Tocagen Inc (TOCA) Upgraded at Zacks Investment Research

Tocagen Inc (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

Separately, Stifel Nicolaus reaffirmed a “buy” rating and issued a $24.00 price target on shares of Tocagen in a research note on Tuesday, July 25th.

Shares of Tocagen (NASDAQ:TOCA) opened at 12.66 on Thursday. The stock’s market cap is $250.78 million. Tocagen has a 1-year low of $9.68 and a 1-year high of $17.95. The firm has a 50-day moving average price of $12.39 and a 200-day moving average price of $13.40.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Equities analysts forecast that Tocagen will post ($2.51) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Tocagen Inc (TOCA) Upgraded at Zacks Investment Research” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/21/tocagen-inc-toca-upgraded-at-zacks-investment-research.html.

Several institutional investors have recently made changes to their positions in the company. TD Asset Management Inc. purchased a new stake in shares of Tocagen in the 2nd quarter valued at $158,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Tocagen in the 2nd quarter valued at $165,000. Alps Advisors Inc. purchased a new stake in shares of Tocagen in the 2nd quarter valued at $215,000. Bank of New York Mellon Corp purchased a new stake in shares of Tocagen in the 2nd quarter valued at $281,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Tocagen in the 2nd quarter valued at $837,000. 37.87% of the stock is currently owned by institutional investors and hedge funds.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply